Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Legalon SIL for prevention and treatment of hepatitis C recurrence after orthotopic liver transplantation
2010-019505-42Phase 2Active
- Sponsor
- Rottapharm Biotech
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing Legalon SIL with Placebo (2 arms). Primary endpoints: Sustained virologic response and Prevention of HCV re-infection after liver transplantation. Started Apr 2010; status: active.
02
Drugs
Legalon SIL
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-019505-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019505-42.